Abstract 17P
Background
Breast cancer is the most common cancer in women in Poland. In patients with cancer located on the left side, breast radiotherapy is associated with the irradiation of part of the heart. It was calculated that for every 1 Gy dose of radiation deposited in the heart, the risk of heart complications increases by 7.4%.
Methods
The subject of analysis was a group of 50 patients treated in the National Institute of Oncology, Department of Radiotherapy, Gliwice from June 2018 to December 2019. The age of patients ranged from 30 to 70 (median 63 years). All patients were after surgeries (38 patients after BCT with SNB and 12 patients after left breast amputation). All patients were additionally irradiated using Deep Inspiratory Breath Hold technique. Dose distributions per heart and lungs were compared in IMRT, Rapid Arc, and DIBH techniques. Radiation complications from the skin were assessed according to WHO scale.
Results
In all irradiated patients the dose distribution in the technique on suspended inhalation was better compared to the dynamic IMRT and Rapid Arc techniques, with dose reduction per heart by about 10-15% and per lung from 5 to 10%. No higher than II degree of acute and late skin reaction in the DIBH technique was observed in comparison with dynamic techniques.
Conclusions
1) Deep Inspiratory Breath Hold technique is a simple non-invasive method which effectively reduces the dose of radiation absorbed by the heart muscle. 2) Irradiation of patients with deep inspiratory allows a reduction of the lungs dose by about 5-10 %. 3) The technique of irradiation of patients during deep inspiratory is a simple, non-invasive method of treatment of patients reducing the risk of radiation complications from the heart and the lungs in comparison with dynamic, IMRT, and Rapid Arc techniques.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors” without further recourse to the authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
211P - The impact of low muscle mass to overall survival in bladder cancer patients undergoing chemotherapy: A systematic review and meta-analysis
Presenter: Karunia Japar
Session: e-Poster Display Session
212P - Stage I non-seminoma testicular cancer: Adjuvant management and outcomes
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
213P - Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
214P - Study of treatment outcome in adults with TFE related RCC
Presenter: Ajaykumar Singh
Session: e-Poster Display Session
215P - Analysis of spatial heterogeneity of responses in metastatic sites with nivolumab in renal cell carcinoma
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
216P - Clinical profile and treatment outcome of testicular seminoma treated at tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
220P - A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
Presenter: Winnie Sung
Session: e-Poster Display Session
221P - Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
Presenter: Hiroji Uemura
Session: e-Poster Display Session
222P - Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
Presenter: Matthew R. Smith
Session: e-Poster Display Session
223P - Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)
Presenter: Karim Fizazi
Session: e-Poster Display Session